Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis-A one-year prospective study
| Autor: | Tatiana, Rozov, Viviane Ziebell, de Oliveira, Maria Angélica, Santana, Fabíola Villac, Adde, Rita Heloisa, Mendes, Ilma Aparecida, Paschoal, Francisco J, Caldeira Reis, Laurinda Yoko Shinzato, Higa, Antonio Carlos de Castro, Toledo, Márcia, Pahl, Lívia, Martins |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Pediatrics medicine.medical_specialty Adolescent Cystic Fibrosis Cystic fibrosis Quality of life Forced Expiratory Volume medicine Deoxyribonuclease I Humans Statistical analysis Prospective Studies Child Prospective cohort study Expectorants Health related quality of life business.industry Respiratory disease Dornase alfa medicine.disease Confidence interval Pediatrics Perinatology and Child Health Quality of Life Female business Brazil medicine.drug |
| Zdroj: | Pediatric Pulmonology. 45:874-882 |
| ISSN: | 8755-6863 |
| Popis: | Background Health-related quality of life (HRQOL) measurements provide valuable information about the psychological and social impact of treatment on patients with cystic fibrosis (CF). This study evaluated the HRQOL of Brazilian patients with CF and assessed the changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme) introduction. Patients and Methods One hundred fifty-six stable patients with CF and 89 caregivers answered the Portuguese-validated version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline (T0), and at 3 (T1), 6 (T2), 9 (T3), and 12 (T4) months of follow-up. Eighteen patients were excluded because they did not fulfill the inclusion criteria. The patients were analyzed in two groups: those aged 6–11 years and those aged 14 years and older. ANOVA for observed repeated results and the last observation carried forward (LOCF) method for missing data were used for the statistical analysis. Results After 1 year of follow-up, there was significant improvement in respiratory symptoms (T4 − T0 = 8.1; 95% confidence interval (95% CI) = [2.1;14.0]; effect size (ES) = 0.35; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text